Urinary Tract Infections (UTI)

Gut Dysbiosis Identified in Women With Recurrent UTI

Publish Date May 24, 2022

Gut microbiome of women with a history of recurrent UTI depleted in microbial richness, butyrate-producing bacteria

Role of Race in Calculating UTI Risk in Children Reassessed

Publish Date April 22, 2022

Race as a variable in risk prediction model can be replaced by history of UTI and duration of fever without affecting accuracy

Antibiotic Stewardship Increases Use of Guideline-Concordant Antibiotics for UTI

Publish Date April 18, 2022

Researchers conducted a study to assess the effect of an antibiotic stewardship program on the use of appropriate antibiotic therapy among patients with urinary tract infections in the ED.

Oral Tebipenem Effectively Treats Complicated UTI, Pyelonephritis

Publish Date April 7, 2022

Tebipenem pivoxil hydrobromide is an orally bioavailable carbapenem with activity against uropathogenic Enterobacterales.

Cefepime-Taniborbactam Bests Meropenem in Complicated UTI Trial

Publish Date March 18, 2022

The phase 3 CERTAIN-1 study compared the efficacy and safety of cefepime-taniborbactam to meropenem in 661 adults with cUTI.

Nonantibiotic Prophylaxis Noninferior for Recurrent UTI

Publish Date March 14, 2022

Incidence of antibiotic-treated UTI during 12-month treatment period noninferior for methenamine hippurate versus prophylactic antibiotics

MV140 Vaccine May Prevent Recurrent Urinary Tract Infections

Publish Date March 2, 2022

MV140 is a sublingual vaccine of whole-cell inactivated bacteria that may be an alternative to frequent antibiotics for recurrent urinary tract infections.

Fosfomycin May Have Place in Treating Drug-Resistant Bacteremic UTIs

Publish Date January 20, 2022

In a study, IV fosfomycin appeared less effective than IV ceftriaxone or meropenem for bacteremic UTI caused by multidrug-resistant E. coli, but the drug may be considered for selected patients with these infections, according to investigators.

Safety, Efficacy of Aminoglycosides or Polymyxin Monotherapy for Complicated UTI

Publish Date January 18, 2022

Researchers conducted a study to assess the safety and efficacy of aminoglycosides or polymyxin monotherapy for the treatment of adults with complicated urinary tract infections caused by extensively drug-resistant Pseudomonas aeruginosa.

Tebipenem HBr Gets Priority Review for Oral Treatment of Complicated UTI

Publish Date January 7, 2022

The application includes data from the phase 3 ADAPT-PO trial, which evaluated the efficacy and safety of tebipenem HBr in 868 adults with cUTI or acute pyelonephritis.